Similar articles for PMID: 28108364

Year	Number of Results
2002	1
2006	1
2007	1
2008	1
2010	2
2011	2
2012	1
2013	2
2014	11
2015	22
2016	22
2017	22
2018	14
2019	8
2020	7
2021	6
2022	2
2023	2
2024	0

1

From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.

Harrer A, Pilz G, Oppermann K, Sageder M, Afazel S, Haschke-Becher E, Rispens T, de Vries A, McCoy M, Stevanovic V, Hitzl W, Trinka E, Kraus J, Sellner J, Wipfler P. Harrer A, et al. Clin Immunol. 2017 Mar;176:87-93. doi: 10.1016/j.clim.2017.01.001. Epub 2017 Jan 17. Clin Immunol. 2017. PMID: 28108364

2

Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.

Laribi B, Sahraian MA, Shekarabi M, Emamnejad R, Marzban M, Sadaghiani S, Izad M. Laribi B, et al. Iran J Allergy Asthma Immunol. 2018 Aug 12;17(4):346-360. doi: 10.18502/ijaai.v17i4.94. Iran J Allergy Asthma Immunol. 2018. PMID: 30537798 Free article.

3

Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.

Song ZY, Yamasaki R, Kawano Y, Sato S, Masaki K, Yoshimura S, Matsuse D, Murai H, Matsushita T, Kira J. Song ZY, et al. PLoS One. 2015 Apr 28;10(4):e0124923. doi: 10.1371/journal.pone.0124923. eCollection 2014. PLoS One. 2015. PMID: 25919001 Free PMC article.

4

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.

Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg Sørensen P. Koch-Henriksen N, et al. Mult Scler. 2017 Feb;23(2):234-241. doi: 10.1177/1352458516643393. Epub 2016 Jul 11. Mult Scler. 2017. PMID: 27055806

5

Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients.

Kowarik MC, Astling D, Lepennetier G, Ritchie A, Hemmer B, Owens GP, Bennett JL. Kowarik MC, et al. Neurotherapeutics. 2021 Jan;18(1):364-377. doi: 10.1007/s13311-020-00975-7. Epub 2020 Nov 30. Neurotherapeutics. 2021. PMID: 33258072 Free PMC article.

6

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.

Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK. Stüve O, et al. Arch Neurol. 2006 Oct;63(10):1383-7. doi: 10.1001/archneur.63.10.1383. Arch Neurol. 2006. PMID: 17030653 Clinical Trial.

7

Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.

Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T, Derfuss T. Naegelin Y, et al. Mult Scler Relat Disord. 2018 Oct;25:14-20. doi: 10.1016/j.msard.2018.07.005. Epub 2018 Jul 6. Mult Scler Relat Disord. 2018. PMID: 30014876 Free article.

8

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.

Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database. Iaffaldano P, et al. Brain. 2015 Nov;138(Pt 11):3275-86. doi: 10.1093/brain/awv260. Epub 2015 Sep 11. Brain. 2015. PMID: 26362907

9

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.

Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, Axelsson M, Malmeström C, Fink K, Lycke J, Svenningsson A, Piehl F. Alping P, et al. Ann Neurol. 2016 Jun;79(6):950-8. doi: 10.1002/ana.24651. Epub 2016 Apr 20. Ann Neurol. 2016. PMID: 27038238 Clinical Trial.

10

High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.

Harrer A, Pilz G, Wipfler P, Oppermann K, Sellner J, Hitzl W, Haschke-Becher E, Afazel S, Rispens T, van der Kleij D, Trinka E, Kraus J. Harrer A, et al. Clin Exp Immunol. 2015 Jun;180(3):383-92. doi: 10.1111/cei.12590. Epub 2015 Apr 27. Clin Exp Immunol. 2015. PMID: 25603898 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

103 results

Results by year